Pattern of practice of re-irradiation for ipsilateral breast tumor recurrence in Italy: a survey by the Italian Association of Radiotherapy and Clinical Oncology (AIRO)

• Mariangela Massaccesi ^[3] ; Antonella Fontana ^[4] ; Isabella Palumbo ^[1] ; Angela Argenone ^[5] ; Maria Carmen De Santis ^[6] ; Valeria Masiello ^[3] ; Antonio Pontoriero ^[2] ; Antonella Ciabattoni ^[7]
  1. [1] Università di Perugia

     Università di Perugia

     Perusa, Italia

     
  2. [2] University of Messina

     University of Messina

     Mesina, Italia

     
  3. [3] Radiation Oncology Unit, Department of Radiology, Radiation Oncology and Hematology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
  4. [4] Radiotherapy Department, Santa Maria Goretti Hospital, Latina, Italy
  5. [5] Radiotherapy Department, San Pio Hospital, Benevento, Italy
  6. [6] Radiation Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
  7. [7] Radiotherapy Department, San Filippo Neri Hospital, Rome, Italy

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 3, 2024, págs. 644-652
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose The Re-irradiation and the Breast Cancer Working Groups of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) conducted a survey to provide an overview of the policies for breast cancer (BC) re-irradiation (re-RT) among the Italian radiotherapy (RT) centers.

    Methods In October 2021, 183 RT centers were invited to answer a survey: after an initial section about general aspects, the questionnaire focused on radiation oncologists’ (ROs) attitude toward re-RT in three different scenarios: ipsilateral breast tumor recurrence (IBTR) treated with second conservative surgery, IBTR treated with mastectomy and inoperable IBTR. Surveyed ROs were also asked to express their interest in being involved in a prospective trials.

    Results Seventy-seven/183 (42.0%) centers answered the Survey, only one RO per center was requested to answer. In particular, 86.5% ROs declared to have performed “curative” re-RT for IBTR during the previous two years (2019–2020): 76.7% respondents administered re-RT after second BCS, 50.9% after mastectomy, and 48.1% for inoperable IBTR. Re-RT practice varied widely among centers in terms of treatment volumes, dose and fractionation schedules, techniques and dose-volume constraints for organs at risks (OARs). Forty-six participants (59.7%) expressed their interest in participating in a prospective study investigating BC re-RT.

    Conclusions About one out of three RT centers in Italy delivered re-RT for IBTR. Nevertheless, practice of re-RT varied widely among centers highlighting the needs for prospective studies to improve knowledge in this field.